

TABLE OF CONTENT

APPROVAL PAGE.....	2
STATEMENT PAGE.....	3
FOREWORD.....	4
TABLE OF CONTENT.....	6
LIST OF TABLE.....	8
LIST OF FIGURES.....	9
CHAPTER I INTRODUCTION.....	10
A. Background.....	10
B. Problem Formulation.....	12
C. Study Objectives.....	12
D. Research Benefits.....	13
E. Study Originality.....	13
CHAPTER II LITERATURE REVIEW.....	17
A. LITERATURE REVIEW.....	17
1. Definition of Glaucoma.....	17
2. Glaucoma Risk Factors.....	18
3. Pathogenesis & Pathophysiology of Glaucoma.....	19

4. Prevalence and Classification of Glaucoma.....	21
5. Cyclin Dependent Kinase Inhibitor Gene Definition.....	22
6. Relationship between Cyclin Dependent Kinasi Inhibitor (CDKN) and Primary Open Angle Glaucoma (POAG).....	24
B. THEORETICAL FRAMEWORK.....	25
C. CONCEPTUAL FRAMEWORK.....	26
CHAPTER III RESEARCH METHOD.....	27
A. Study Design.....	27
Procedure.....	27
B. Study Time and Setting.....	28
C. Study Population.....	28
D. Data Collection Tools.....	28
E. Study Variable.....	29
F. Operational Definition.....	29
G. Study Plan.....	30
H. Statistical Analysis.....	31
I. Ethical Consideration.....	31
J. Study Timeline.....	31

CHAPTER IV RESEARCH RESULT AND DISCUSSION.....	33
A. General Overview of Findings.....	33
B. Baseline Characteristics of Participants.....	34
C. Genetic Variants identified in Primary Open Angle Glaucoma (POAG) Patients.....	36
D. Comparison of RS1063192 Variant Frequency in Primary Open Angle Glaucoma (POAG) and non-POAG Patients.....	42
CHAPTER V CONCLUSION AND SUGGESTION.....	44
A. Conclusion.....	44
B. Research Limitation.....	45
C. Suggestion.....	45
BIBLIOGRAPHY.....	46